Amgen Loses Battle In Anemia War With La Roche
But the ITC’s ruling doesn’t give Hoffman-La Roche (Roche) a green light to manufacture and sell their anti-anemia drug CERA in the U.S. The ruling only allows Roche to import and use peg-EPO for use in clinical trials.
Amgen was quick to point out that the ITC’s decision...
To view the full article, register now.